Status:
UNKNOWN
Outcome of Tucidinostat-Based Therapy in HR+ Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitor
Lead Sponsor:
Beijing 302 Hospital
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
To evaluate the efficacy of tucidinostat-based therapy in hormone receptor-positive metastatic breast cancer patients previously treated with CDK4/6 inhibitor therapy in the real world.
Detailed Description
Cyclin-dependent kinase (CDK) 4/6 inhibitors have changed the treatment pattern of patients with hormone receptor-positive HER2-negative advanced breast cancer significantly prolongling patients'PFS a...
Eligibility Criteria
Inclusion
- woman, age \> 18 years old 2.Diagnosed with HR+/HER2- Metastatic Breast Cancer 3.Patients received tucidinostat-based therapy after progression on CDK4/6 inhibitor 4.Complete medical history was available
Exclusion
- Medical history was incomplete
Key Trial Info
Start Date :
July 10 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2022
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05276713
Start Date
July 10 2019
End Date
August 1 2022
Last Update
March 11 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Fifth Medical Center of PLA General Hospital
Beijing, Beijing Municipality, China, 100071